Negara: Australia
Bahasa: Inggris
Sumber: Department of Health (Therapeutic Goods Administration)
Bicisate dihydrochloride
Lantheus MI Australia Pty Ltd
Medicine Registered
NEUROLITE Technetium Tc-99m Bicisate dihydrochloride CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about Neurolite. It does not contain all of the available information about Neurolite. It does not replace talking to your doctor. All medicines have risks and benefits. Your doctor has weighed the risks of you or your child receiving Neurolite against the benefits he or she expects it will have. IF YOU HAVE ANY CONCERNS ABOUT HAVING THIS MEDICINE, ASK YOUR DOCTOR. KEEP THIS LEAFLET. You may need to read it again. WHAT IS NEUROLITE Neurolite contains the active ingredient is called _Technetium Tc-99m_ _Bicisate _ _dihydrochloride_ and belongs to a group of medicines called radiopharmaceutical agents, which are all radioactive. Neurolite comes as a kit, containing ingredients that are mixed with a radioactive solution before being given to you as an injection. WHAT NEUROLITE IS USED FOR Neurolite is used to show the blood flow inside your brain during the scan. Your doctor may have prescribed Neurolite for another purpose. Ask your doctor if you have any questions about why Neurolite has been prescribed for you. If you have any concerns, you should discuss these with your doctor. This medicine is only available with a doctor’s prescription. BEFORE YOU ARE GIVEN NEUROLITE Before you are given Neurolite your doctor will explain to you the procedure you are about to undergo, and the radioactive medicine you will be given. You must discuss any concerns you have with your doctor. Neurolite is not recommended for patients less than 18 years of age. If your doctor believes it is necessary to give Neurolite to a patient under 18, he or she will discuss the benefits and risks with you. 2 YOU MUST TELL YOUR DOCTOR Baca dokumen lengkapnya
513068-0110 January 2010 NEUROLITE ® Kit for the Preparation of Technetium [ 99m Tc] Bicisate Injection FOR DIAGNOSTIC USE DESCRIPTION This kit formulation consists of two nonradioactive vials: Vial A contains bicisate dihydrochloride (N, N’- 1,2-ethylenediylbis-L-cysteine diethyl ester dihydrochloride) and a reducing agent as a lyophilized solid and Vial B contains a buffer solution. Both vials are sterile, non-pyrogenic, and contain no preservative. VIAL A – Bicisate dihydrochloride (ECD•2HCl) 0.9 mg Disodium edetate, dihydrate 0.36 mg Mannitol 24 mg Stannous chloride, dihydrate, (SnCl 2 •2H 2 O) 72 μg Stannous chloride, dihydrate, minimum (SnCl 2 •2H 2 O) 12 μg The contents of vial A are lyophilized and stored under nitrogen. The pH of the solution before lyophilization is 2.7 ± 0.25. This vial is stored at below 25°C. Protect from light. VIAL B – Sodium phosphate dibasic heptahydrate 4.1 mg Sodium phosphate monobasic monohydrate 0.46 mg Water for Injection qs 1 mL The contents of vial B are stored under air. The pH of the solution is 7.6 ± 0.4. This vial is stored at below 25°C. This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non- pyrogenic, Sodium Pertechnetate [ 99m Tc[ Injection BP. The precise structure of the Technetium complex is [N, N’-ethylenedi-L-cysteinato(3-)]oxo[ 99m Tc] technetium (V), diethyl ester. PHYSICAL CHARACTERISTICS Technetium [ 99m Tc] decays by isomeric transition with a physical half-life of 6.02 h Baca dokumen lengkapnya